How can we support patients with EGFR-mutant early-stage NSCLC throughout treatment? Dr. James Yang explores biomarker testing, treatment duration, adverse event management, and shared decision-making in our latest touchEXPERT FOCUS. ▶️ Watch & earn CME
- 2 réponses
- 0 partages
- 43 j'aime
- 1 833 117 vues








